Equivalent humoral and cellular immune response but different side effect rates following SARS-CoV-2 vaccination in peritoneal and haemodialysis patients using messenger RNA vaccines

Stumpf, Julian; Klimová, Anna; Mauer, René; Steglich, Anne; Gembardt, Florian; Martin, Heike; Glombig, Grit; Frank, Kerstin; Tonn, Torsten; Hugo, Christian

doi:10.1093/ndt/gfab324

Cited by 8 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whether this antibody decline difference relates to potential differences in the clearance of uremia related substances is unclear. In contrast, seroconversion rates for both SARS-CoV-2 22 or Hepatitis B 23 vaccination are equivalent in hemodialysis and peritoneal dialysis patients.…”

Section: Discussionmentioning

confidence: 88%

Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study

Stumpf

Schwöbel²,

Lindner

et al. 2022

The Lancet Regional Health - Europe

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 88%

Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study

Stumpf

Schwöbel²,

Lindner

et al. 2022

The Lancet Regional Health - Europe

Self Cite

View full text Add to dashboard Cite

“…Mannose-modified lipid calcium phosphate nanoparticle vaccine is a novel tumor immunotherapy method that can enhance the immune response to tumors by regulating the tumor microenvironment [213]. Studies [214][215][216][217][218][219][220] have shown that the vaccine can activate the body's immune system, promote the expression and recognition of tumor-associated antigens, and trigger a specific immune response against tumor cells. Through mannose modification, the vaccine can be more effectively taken up by antigen-presenting cells and improve its efficiency of antigen delivery in the lymph nodes, further activating immune cells such as dendritic cells and T cells and enhancing the potential of the immune response [221].…”

Section: Enhancement Of Tumor Immune Response and Establishment Of Im...mentioning

confidence: 99%

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

Wu,

Qian,

et al. 2024

Preprint

View full text Add to dashboard Cite

With the rapid development of tumor immunotherapy, nanoparticle vaccines have attracted much attention as a potential therapeutic strategy. The potential role of the mannose-modified lipid calcium phosphate nanoparticle vaccine in enhancing the anti-tumor immune response was investigated. The aim of this study was to investigate the effect of mannose modification on the immune response of nanoparticles in regulating the tumor microenvironment through systematic review and analysis and to explore its potential clinical application in tumor therapy. Currently, despite the potential advantages of nanoparticle vaccines in immunotherapy, achieving an effective immune response in the tumor microenvironment remains a challenge. Tumor immune escape and overexpression of immunosuppressive factors limit its clinical application. Therefore, this study will explore how to intervene in the immunosuppressive mechanism in the tumor microenvironment through mannose-modified lipid calcium phosphate nanoparticle vaccines so as to improve the immunotherapy effect of tumor patients and provide new ideas and strategies for the field of tumor therapy.

show abstract

“…In a comparison of the incidence of side-effects of the mRNA COVID-19 vaccine in patients treated with hemodialysis and patients treated with peritoneal dialysis, Stumpf et al found that patients treated with peritoneal dialysis had a higher incidence of vaccination-related side-effects, such as fever and vaccination site pain, than patients treated with hemodialysis. The authors speculated that this difference may be related to the fact that patients treated with hemodialysis have become accustomed to repetitive puncture pain and chronic microinflammation due to blood membrane contact, whereas patients treated with peritoneal dialysis are not [ 79 ]. Zitt et al evaluated the safety of the BNT162b2 mRNA vaccine in 50 patients on hemodialysis with a mean age of 67.6 years.…”

Section: Safety Of Covid-19 Vaccination In Patients Treated With Hemo...mentioning

confidence: 99%

The prevention and treatment of COVID-19 in patients treated with hemodialysis

Zeng,

Zhou,

Peng

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Patients treated with hemodialysis are often immunocompromised due to concomitant disease. As a result, this population is at high risk of infection and mortality from COVID-19. In addition to symptomatic treatment, a series of antiviral drugs targeting COVID-19 are now emerging. However, these antivirals are used mainly in mild or moderate patients with high-risk factors for progression to severe disease and are not available as pre- or post-exposure prophylaxis for COVID-19. There is a lack of clinical data on the use of anti-COVID-19 drugs, especially in patients treated with hemodialysis, therefore, vaccination remains the main measure to prevent SARS-CoV-2 infection in these patients. Here, we review the clinical features and prognosis of patients on hemodialysis infected with SARS-CoV-2, the main anti-COVID-19 drugs currently available for clinical use, and the safety and efficacy of anti-COVID-19 drugs or COVID-19 vaccination in patients treated with hemodialysis. This information will provide a reference for the treatment and vaccination of COVID-19 in patients treated with hemodialysis and maximize the health benefits of these patients during the outbreak.

show abstract

Equivalent humoral and cellular immune response but different side effect rates following SARS-CoV-2 vaccination in peritoneal and haemodialysis patients using messenger RNA vaccines

Cited by 8 publications

References 10 publications

Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study

Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study

A Mannose-Modified Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Anti-Tumor Immune Response by Modulating the Tumor Microenvironment

The prevention and treatment of COVID-19 in patients treated with hemodialysis

Contact Info

Product

Resources

About